Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients: A retrospective analysis of a general practice study

American Journal of Cardiovascular Drugs

Volumn 4, Issue 3, 2004, Pages 195-200

  Meredith, Peter A ^a   Reid, John L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMIDAZOLINE I1 RECEPTOR; RILMENIDINE;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LIPID METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS; DIASTOLE; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; OXAZOLES; RETROSPECTIVE STUDIES; SYSTOLE; TIME; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 2942643960     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404030-00006     Document Type: Article

References (29)

1. Arauz-Pacheco C, Parrot MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 125: 134-47
2. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and hypertensive therapy as the risk factor for type 2 diabetes. Atherosclerosis Risk in Communities Study. N Fngl J Med 2000; 342: 905-12
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
4. Hansson L, Zanchetti A, Carruthers G, et al. for the Hypertension Optimal Treatment (HOT) Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the HOT randomised trial. Lancet 1998; 351: 1755-62
5. United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
6. The Sixth Report of the Joint National Committee on prevention detection, evaluation and treatment of high blood pressure. Arch Int Med 1997; 157: (21) 2413-46
7. World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: (2) 151-83
8. Chowdhury TA, Kumar S, Rocella EJ, et al. Prevalence of hypertension in patients with type 2 diabetes: a review of the recent evidence. J Hum Hypertens 1999; 13: 803-11
9. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001; 161: 10-24
10. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8
11. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
13. Louis WJ, O'Callaghan PR, Conway EL, et al. Centrally acting drugs. In: Swales J, editor. Textbook of hypertension. London: Blackwell Scientific, 1994: 1033-45
14. Bricca G, Dontenwil M, Feldman J, et al. Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989; 163: 373-7
15. De Luca N, Izzo R, Fontana D, et al. Haemodynamic and metabolic effect of rilmenidine in hypertensive patients with metabolic syndrome X A double-blind parallel study versus amlodipine. J Hypertens 2000; 18: 1515-22
16. Bauduceau B, Mayaudon H, Dupuy O. Efficacy of rilmenidine selective II imidazoline receptor agent, in hypertensive diabetics. J Cardiovasc Risk 2000; 7: 57-61
17. Trimarco B. Contribution of an I1 selective agent in the management of hypertensive patients with metabolic syndrome X [abstract]. Am J Hypertens 1999; 12: 221A
18. Luccioni R. Efficacy and acceptability of rilmenidine in 18 235 hypertensive patients over 1 year. Presse Med 1995; 124: 1827-64
19. Izzo JL, Levy D, Black HR. Clinical advisory statement: importance of systolic blood pressure in older Americans. Hypertension 2000; 5: 1021-4
20. Fiorentin C, Guillet C, Guazzi M. Etude multicentrique italiennne en double aveugle comparant la rilménidine 1mg et l'hydrochlorothiazide 25mg chez 444 patients. Arch Mal CØur Vaiss 1989; 82: 39-46
21. Scemama M, Fevrier B, Beucler I, et al. Lipid profile and hypertensive patients: comparison of rilmenidine and captopril. J Cardiovasc Pharmacol 1995; 26 Suppl 2: S34-9
22. Pelemans W, Verhaeghe J, Creytens C, et al. Efficacy and safety of rilmenidine in elderly patients: comparison with hydrochlorothiazide. The Belgium Multicenter Study Group. Am J Cardiol 1994; 74: 51-57A
23. Reaven G. Role of insulin resistance and the sympathoadrenal system. Diabetes 1988; 37: 1595-160
24. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199-201
25. Kaplan NM. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-20
26. Penicaud L, Berthault MF, Mono J, et al. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens 1998; 16 Suppl. 3: S45-9
27. Julius S, Majahalme S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 2001; 14: 310-316S
28. Soergel M, Schaefer F. Effect of hypertension on the progression of chronic renal failure in children. Am J Hypertens 2002; 15: 53-56S
29. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857-63